WAINZUA
WAINZUA is a medicine authorised by Swissmedic under authorisation number 69332. The authorisation holder is AstraZeneca AG. The medicinal product code is Transplant: gene therapy product and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 14 February 2025 and the authorisation is limited until 13 February 2030. ATC code N07XX21 places the medicine in the group Other nervous system drugs.
| Authorisation number | 69332 |
|---|---|
| Name | WAINZUA |
| Full name | WAINZUA, Injektionslösung |
| Authorisation holder | AstraZeneca AG |
| Medicinal product code | Transplant: gene therapy product |
| Dispensing category | B · Prescription only |
| ATC code | N07XX21 |
| First authorisation | 14 February 2025 |
| Authorisation validity | 13 February 2030 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | WAINZUA, Injektionslösung | B | 14 February 2025 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Einzeldose(n) | N07XX21 | 01.99.0. | B |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is WAINZUA authorised in Switzerland?
Yes. WAINZUA is authorised by Swissmedic under authorisation number 69332, data as of 01 September 2026. The authorisation is limited until 13 February 2030.
Which dispensing category does WAINZUA have?
WAINZUA is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of WAINZUA?
The authorisation holder is AstraZeneca AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.